


CCR8 antagonist 2

| | |
|---------------------------|--|
| Cat. No.: | HY-144200 |
| CAS No.: | 2756350-98-6 |
| Molecular Formula: | C ₂₃ H ₃₀ ClN ₃ O ₃ S |
| Molecular Weight: | 464.02 |
| Target: | CCR |
| Pathway: | GPCR/G Protein; Immunology/Inflammation |
| Storage: | 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 4 mg/mL (8.62 mM; ultrasonic and warming and heat to 60°C)

| Concentration | Mass | | |
|---------------|-----------|------------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 2.1551 mL | 10.7754 mL | 21.5508 mL |
| 5 mM | 0.4310 mL | 2.1551 mL | 4.3102 mL |
| 10 mM | --- | --- | --- |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220)^[1].

IC₅₀ & Target

CCR8

REFERENCES

[1]. Guohuang FAN, et al. Methods and compositions for targeting tregs using ccr8 inhibitors.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA